Table 1.
Clinical data, histology diagnosis and 2-deoxy-2-[18F]fluoro-D-glucose (FDG) as well as [11C]methyl-L-tryptophan (AMT) PET standard uptake values measured in each lesion of the 10 patients
| No. | Sex/Age (yrs) | Diagnosis | Previous therapy (before AMT) | Time between FDG/AMT PET | Lesion number | SUV FDG | SUV AMT |
|---|---|---|---|---|---|---|---|
| #1 | F/54 | Thymic cyst | none | FDG PET not done | 1 | - | 0.5 |
| #2 | M/39 | Hamartoma | none | 54days (FDG later) | 1 | 0.9 | 0.7 |
| #3 | M/66 | Metastasis (rectal cancer) | none | 11days | 1 | 2.8 | 1.3 |
| #4 | M/58 | NSCLC [scc] | Chemoth. (2weeks)* | 1 month | 1 | 15.7 | 2.5 |
| #5 | F/58 | NSCLC [pd] | Radio+Chemotherapy (> 6 months)** | 1 month | 1 | 8.0 | 5.5 |
| 2 | 6.8 | 4.4 | |||||
| #6 | F/56 | NSCLC [lcc] | Radio+Chemoth (> 6months)** | 7 days | 1 | 5.5 | 2.4 |
| 2 | 2.8 | 2.7 | |||||
| 3 | 3.0 | 2.6 | |||||
| 4 | 2.7 | 1.6 | |||||
| 5 | 2.7 | 2.7 | |||||
| #7 | M/79 | NSCLC [acc] | none | 6 days | 1 | 2.8 | 1.2 |
| #8 | M/49 | NSCLC [scc] | none | 11 days | 1 | 7.3 | 2.1 |
| 2 | 3.3 | 1.7 | |||||
| #9 | F/47 | NSCLC [acc] | none | FDG PET not done | 1 | - | 3.2 |
| 2 | - | 3.0 | |||||
| #10 | M/46 | NSCLC [pd] | none | 28 days | 1 | 4.7 | 1.9 |
| 2 | 1.6 | 0.8 |
NSCLC = non-small cell lung cancer; tumors are consecutively numbered in patients with multiple lesions
scc: squamous cell carcinoma; lcc: large cell carcinoma; acc: adenocarcinoma; pd: poorly differentiated carcinoma
*
therapy started after FDG PET but 2 weeks before AMT PET scan
**
therapy was finished more than 6 months before AMT PET scan